What is the therapeutic effect of dabrafenib mesylate capsules combined with trametinib?

Dabrafenib mesylate capsules (Tafinlar) and trametinib tablets (Mekinist) are manufactured by Novartis ( or GlaxoSmithKline, depending on the region and market conditions), the former is a BRAF inhibitor and the latter is a MEK inhibitor. BRAF and MEK are key molecules in the MAPK signaling pathway. Abnormal activation of this pathway is closely related to the occurrence and development of various tumors. BRAF V600Mutation is a common driver gene mutation in various tumors such as melanoma and non-small cell lung cancer. Targeted therapy for this mutation has become one of the important treatments for these tumors.

In the treatment of melanoma, dabrafenib combined with trametinib, as a standard treatment option for patients with BRAF V600 mutations, has demonstrated excellent clinical effects. For example, the COMBI-AD study is a study of stage IIIresectedBRAF A double-blind, randomized, placebo-controlled Phase III clinical trial in patients with V600E or V600K mutant melanoma. The results of the study showed that compared with the placebo group, the relapse-free survival (RFS) of patients in the dabrafenib combined with trametinib group was significantly prolonged, and the 5 yearRFS rates were 52 respectively. % and 36% (risk ratio 0.51, 95%CI: 0.42-0.61). In addition, the risk of recurrence or death in the combination treatment group was reduced by 49%, and no obvious long-term toxic and side effects were observed.

ForBRAF V600EIn patients with mutation-positive metastatic non-small cell lung cancer, dabrafenib combined with trametinib also showed good therapeutic effects. Results from a multicenter, 3cohort, non-randomized, activity-evaluated, open-label clinical trial showed that the overall response rate of the combination regimen was 61% (95% CI: 48-74 ) , the median duration of response (DOR) was 9 months (95% CI: 5.8-26.2) [3] . These data indicate that dabrafenib combined with trametinib is expected to become one of the first-choice treatment options for patients with BRAF V600E mutation-positive non-small cell lung cancer.

In the treatment of children with low-grade glioma (LGG), dabrafenib combined with trametinib has also shown significant efficacy. Results from a phase 2 clinical trial of BRAF V600 mutated children with LGG showed that patients treated with dabrafenib plus trametinib had a higher overall response rate than those treated with standard chemotherapy (47% vs. 11%), the clinical benefit was more obvious (86% vs. 46%), and the median progression-free survival was significantly longer (20.1 months vs. 7.4 months). In addition, the incidence of adverse events in the combination treatment group was also relatively low, indicating that the treatment regimen is also safe and tolerable in pediatric patients.

The reason why the combined application of dabrafenib and trametinib can achieve significant efficacy in a variety of tumors is mainly due to their synergistic effect. Dabrafenib blocks the abnormal activation of the MAPK signaling pathway by inhibiting the activity of BRAF kinase, while trametinib further inhibits the MEK molecules downstream of this pathway. This dual upstream and downstream blocking can more comprehensively inhibit the growth and spread of tumor cells, thus enhancing the anti-tumor effect. In addition, combined application can also reduce drug resistance problems that may occur during single drug treatment and improve the overall survival rate and quality of life of patients.

The safety and tolerability of dabrafenib combined with trametinib have been verified in multiple clinical studies. Although this combination treatment may cause some side effects, such as rash, diarrhea, nausea, vomiting, etc., most of these reactions are mild to moderate and can be alleviated by adjusting the drug dose or providing symptomatic and supportive treatment. In addition, no obvious long-term toxic and side effects were found during long-term follow-up, further proving the safety and feasibility of this combined treatment regimen.